332 related articles for article (PubMed ID: 8778001)
1. Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM.
Kolterman OG; Schwartz S; Corder C; Levy B; Klaff L; Peterson J; Gottlieb A
Diabetologia; 1996 Apr; 39(4):492-9. PubMed ID: 8778001
[TBL] [Abstract][Full Text] [Related]
2. Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue.
Kolterman OG; Gottlieb A; Moyses C; Colburn W
Diabetes Care; 1995 Aug; 18(8):1179-82. PubMed ID: 7587855
[TBL] [Abstract][Full Text] [Related]
3. Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM.
Kong MF; King P; Macdonald IA; Stubbs TA; Perkins AC; Blackshaw PE; Moyses C; Tattersall RB
Diabetologia; 1997 Jan; 40(1):82-8. PubMed ID: 9028722
[TBL] [Abstract][Full Text] [Related]
4. Effects of the amylin analogue pramlintide on hepatic glucagon responses and intermediary metabolism in Type 1 diabetic subjects.
Orskov L; Nyholm B; Yde Hove K; Gravholt CH; Møller N; Schmitz O
Diabet Med; 1999 Oct; 16(10):867-74. PubMed ID: 10547215
[TBL] [Abstract][Full Text] [Related]
5. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes.
Fineman MS; Koda JE; Shen LZ; Strobel SA; Maggs DG; Weyer C; Kolterman OG
Metabolism; 2002 May; 51(5):636-41. PubMed ID: 11979398
[TBL] [Abstract][Full Text] [Related]
6. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.
Weyer C; Gottlieb A; Kim DD; Lutz K; Schwartz S; Gutierrez M; Wang Y; Ruggles JA; Kolterman OG; Maggs DG
Diabetes Care; 2003 Nov; 26(11):3074-9. PubMed ID: 14578242
[TBL] [Abstract][Full Text] [Related]
7. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
Maggs DG; Fineman M; Kornstein J; Burrell T; Schwartz S; Wang Y; Ruggles JA; Kolterman OG; Weyer C
Diabetes Metab Res Rev; 2004; 20(1):55-60. PubMed ID: 14737746
[TBL] [Abstract][Full Text] [Related]
8. The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus.
Nyholm B; Orskov L; Hove KY; Gravholt CH; Møller N; Alberti KG; Moyses C; Kolterman O; Schmitz O
Metabolism; 1999 Jul; 48(7):935-41. PubMed ID: 10421239
[TBL] [Abstract][Full Text] [Related]
9. Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial.
Thompson RG; Peterson J; Gottlieb A; Mullane J
Diabetes; 1997 Apr; 46(4):632-6. PubMed ID: 9075803
[TBL] [Abstract][Full Text] [Related]
10. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps.
Levetan C; Want LL; Weyer C; Strobel SA; Crean J; Wang Y; Maggs DG; Kolterman OG; Chandran M; Mudaliar SR; Henry RR
Diabetes Care; 2003 Jan; 26(1):1-8. PubMed ID: 12502651
[TBL] [Abstract][Full Text] [Related]
11. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus.
Fineman M; Weyer C; Maggs DG; Strobel S; Kolterman OG
Horm Metab Res; 2002 Sep; 34(9):504-8. PubMed ID: 12384827
[TBL] [Abstract][Full Text] [Related]
12. The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes.
Rodriguez LM; Mason KJ; Haymond MW; Heptulla RA
Pediatr Res; 2007 Dec; 62(6):746-9. PubMed ID: 17957149
[TBL] [Abstract][Full Text] [Related]
13. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus.
Ryan GJ; Jobe LJ; Martin R
Clin Ther; 2005 Oct; 27(10):1500-12. PubMed ID: 16330288
[TBL] [Abstract][Full Text] [Related]
14. The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM.
Kong MF; Stubbs TA; King P; Macdonald IA; Lambourne JE; Blackshaw PE; Perkins AC; Tattersall RB
Diabetologia; 1998 May; 41(5):577-83. PubMed ID: 9628276
[TBL] [Abstract][Full Text] [Related]
15. The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes.
Heptulla RA; Rodriguez LM; Bomgaars L; Haymond MW
Diabetes; 2005 Apr; 54(4):1100-7. PubMed ID: 15793249
[TBL] [Abstract][Full Text] [Related]
16. Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossover Study.
Riddle MC; Nahra R; Han J; Castle J; Hanavan K; Hompesch M; Huffman D; Strange P; Öhman P
Diabetes Care; 2018 Nov; 41(11):2346-2352. PubMed ID: 30213882
[TBL] [Abstract][Full Text] [Related]
17. Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus.
Singh-Franco D; Robles G; Gazze D
Clin Ther; 2007 Apr; 29(4):535-62. PubMed ID: 17617279
[TBL] [Abstract][Full Text] [Related]
18. The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetes.
Amiel SA; Heller SR; Macdonald IA; Schwartz SL; Klaff LJ; Ruggles JA; Weyer C; Kolterman OG; Maggs DG
Diabetes Obes Metab; 2005 Sep; 7(5):504-16. PubMed ID: 16050943
[TBL] [Abstract][Full Text] [Related]
19. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.
Pampanelli S; Torlone E; Ialli C; Del Sindaco P; Ciofetta M; Lepore M; Bartocci L; Brunetti P; Bolli GB
Diabetes Care; 1995 Nov; 18(11):1452-9. PubMed ID: 8722069
[TBL] [Abstract][Full Text] [Related]
20. Effects of 4 weeks' administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations.
Thompson RG; Pearson L; Kolterman OG
Diabetologia; 1997 Nov; 40(11):1278-85. PubMed ID: 9389419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
